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Ann  Daly ,  PhD 14 ,  Christopher P.  Day ,  MD 14 ,  Yong-Fang  Kuo ,  PhD 15 and  Ashwani K.  Singal ,  MD, MS 16 
 OBJECTIVES:  The genetic polymorphism with an isoleucine-to-methionine substitution at position 148 (rs738409 
C>G) in the  patatin-like phospholipase domain protein 3 (PNPLA3 ) gene confers risk of steatosis. 
PNPLA3 polymorphism is shown to be associated with alcoholic liver disease (ALD). We performed a 
systematic review and meta-analysis to examine association of this genetic polymorphism with ALD 
spectrum and its severity.
 METHODS:  Medline, Embase, and Cochrane Library were searched for studies on association of PNPLA3 
polymorphism and ALD spectrum: alcoholic fatty liver (AFL), alcoholic liver injury (ALI), alcoholic 
cirrhosis (AC), and hepatocellular carcinoma (HCC). Pooled data are reported as odds ratio (OR) 
with 95% confi dence interval. Heterogeneity was assessed using the  I 2 statistics and publication 
bias using Egger’s test and Begg and Mazumdar’s test. Individual participant data obtained from fi ve 
studies were used for subgroup analyses.
 RESULTS:  Among 10 studies included in this pooled analysis, compared with controls, OR for rs738409 CG 
and GG among ALI patients was 1.45 (1.24–1.69) and 2.22 (1.50–3.28), respectively, compared 
with CC. Respective OR among AC patients was 2.09 (1.79–2.44) and 3.37 (2.49–4.58) and 
among AC patients with HCC was 2.87 (1.61–5.10) and 12.41 (6.99–22.03). Data for AFL were 
inconsistent. Among ALD patients, OR of CG and GG genotypes was 2.62 (1.73–3.97) and 8.45 
(2.52–28.37), respectively, for AC compared with fatty liver (FL) patients. Similar OR for AC 
compared with ALI was 1.98 (1.24–3.17) and 3.86 (1.18–12.60). The OR for CG and GG genotypes 
among AC patients for HCC occurrence was 1.43 (0.76–2.72) and 2.81 (1.57–5.01), respectively. 
Individual participant data analysis showed age to predispose to AC among ALI patients.
 CONCLUSIONS:  PNPLA3 genetic polymorphism (rs738409 C>G) is associated with increased risk for the entire spectrum 
of ALD among drinkers including ALI, AC, and HCC. Studies are needed to clarify association of PNPLA3 
polymorphism and steatosis in alcoholics.  PNPLA3 gene may potentially be a therapeutic target in ALD.
 SUPPLEMENTARY MATERIAL is linked to the online version of the paper at  http://www.nature.com/ajg 
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 INTRODUCTION
 Alcohol abuse is a common cause of cirrhosis and indication for 
liver transplantation. Clinical spectrum of alcohol-related liver 
disease includes simple steatosis or alcoholic fatty liver (AFL), 
alcoholic liver injury with elevated transaminases but without 
cirrhosis (ALI), alcoholic cirrhosis (AC), and hepatocellular 
carcinoma (HCC). Amount of alcohol consumption is the most 
important factor in the development of ALI and AC ( 1 ). How-
ever, only ∼ 10–20% of heavy drinkers develop AC, suggesting a 
role of other host factors and comorbidities predisposing to ALI 
and its progression to AC and HCC ( 2 ). Data on genetic predis-
position to alcoholism and alcoholic liver disease (ALD) among 
monozygotic twins ( 3 ), and on ethnic variations on ALD-related 
mortality independent of amount of alcohol use, support the 
role of genetic factors in mediating ALD ( 4–6 ). Single-nucleo-
tide polymorphisms within genes of cytokines, alcohol-metab-
olizing enzymes, and antioxidant enzymes have been shown to 
be associated with progression of alcohol-induced liver fi brosis 
( 7 ). However, data on association of these genetic factors in the 
development of ALD have remained confl icting until a few years 
ago ( 8 ).
 Recently, a genome-wide screen in a population of Hispanic, 
African, and European Americans from the Dallas Heart Study 
identifi ed a strong association between a single-nucleotide pol-
ymorphism, rs738409 C>G (causing an isoleucine-to-methio-
nine substitution at position 148, I148M), in the  patatin-like 
phospholipase domain containing protein 3 ( PNPLA3 ) gene and 
hepatic fat content ( 9 ). In addition, a strong association between 
PNPLA3 genotype and elevated alanine aminotransferase levels 
as well as hepatic fat content was confi rmed in other popula-
tions ( 10–16 ). Although this gene was discovered to be asso-
ciated with steatosis in patients with nonalcoholic fatty liver 
disease ( 12 ), data are emerging on its association with other 
liver diseases, including hepatitis C virus cirrhosis ( 17 ) and 
alcoholic cirrhosis ( 18 ). We performed a systematic review and 
meta-analysis of studies to examine the association between the 
presence of the PNPLA3 rs738409 polymorphism and the spec-
trum of ALD.
 METHODS
 Identifi cation and retrieval of primary studies
 We performed search of PubMed/Medline, Embase, and 
Cochrane for full-length articles in English examining PNPLA3 
polymorphism association among ALD patients. We followed the 
MOOSE (Meta-analysis of Observational Studies in Epidemiol-
ogy) guidelines ( 19 ). Th e initial medical subject heading search 
terms were “liver cirrhosis, alcoholic,” and “adiponutrin, human” 
and expanded search using “rs738409” and “patatin-like phospho-
lipase domain-containing 3 protein, human.” All databases were 
searched from their inception through September 2014. Articles 
were selected for full text review based on title and abstract. Man-
ual search of the bibliographies of retrieved publications was done 
by two independent investigators (H.S. and A.K.S.) to increase 
yield of potentially relevant articles.
 Inclusion and exclusion criteria
 Inclusion and exclusion criteria were defi ned at the time of 
study conception and before data collection. For inclusion into 
the meta-analysis, a study had to (i) include patients with alco-
hol dependence; (ii) assess the presence of the PNPLA3 variant 
(rs738409 C>G); (iii) defi ne the ALD spectrum to AFL: steatosis 
on liver ultrasound in the absence of elevated liver enzymes, ALI: 
liver steatosis accompanied by elevated amino transferases in the 
absence of cirrhosis, AC: confi rmed by biopsy or clinical evalua-
tion supported by hematological, biochemical, and/or radiologic 
imaging fi ndings, and HCC: diagnostic fi ndings on triple phase 
magnetic resonance imaging or computed tomography or on his-
tological examination of the liver tissue; and (iv) be published as 
a full-length article. We excluded studies (i) without gene fre-
quency and/or odds ratio (OR) data and (ii) including subjects 
with other liver disease etiologies without separate data among 
ALD patients.
 Study selection and data extraction
 Two reviewers (H.S. and A.K.S.) independently examined 
the studies for the inclusion and exclusion criteria and also 
extracted the data from the studies included in the analysis. Th e 
reviewers resolved discrepancies by jointly reviewing the study 
in question. Studies included in the analysis were reviewed for 
(i) study characteristics: author and year of publication, and 
study design (population based or not, using controls or not); 
(ii) study population: ALD spectrum and the sample sizes; (iii) 
frequencies of PNPLA3 polymorphism genotypes (rs738409 
CC, CG, and GG): among healthy controls and ALD patients; 
and (iv) ORs: for association of PNPLA3 polymorphism and 
spectrum of ALD and for severity of ALD among diseased 
drinkers. Corresponding authors of studies included in the 
analysis were contacted to obtain the individual participant 
data.
 End points and outcomes
 Our study end points were (i) alcohol-related fatty liver (FL), 
ALI, AC, or HCC among drinkers compared with healthy con-
trols and (ii) severity of ALD among drinkers. Healthy controls 
were defi ned as subjects without evidence of AFL, ALI, AC, or 
HCC irrespective of their drinking status as our primary aim was 
to examine the association of PNPLA3 polymorphisms with the 
predisposition to ALD.
 We also performed the subgroup analyses for patient demo-
graphics (age, gender, and ethnicity) using the individual partici-
pant data.
 Assessment of study quality
 Th e quality of included studies was assessed independently 
by two authors (H.S. and A.K.S.) using the Newcastle–Ottawa 
Quality Assessment Scale for case–control studies ( 20 ). Th is 
scale has two diff erent instruments for assessing case–control 
and cohort studies. Each instrument includes measures of 
quality in three domains: selection, comparability, and exposure. 
A study can receive up to one point for each of four areas meas-
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ured within the selection domain and for each of three areas 
measured within the exposure domain. A maximum of two 
points can be assigned within the comparability domain. Th e 
highest possible score is nine. High-quality studies were con-
sidered to have a score of seven or greater. Any discrepancies 
between the two authors were addressed by a joint reevaluation 
of the original article.
 We also assessed the Hardy–Weinberg equilibrium (HWE) to 
assess genotype frequencies in the included studies. As the devia-
tion from HWE in controls has been associated with problems in 
the design and conduct of genetic association studies particularly 
because of population stratifi cation, genotyping error, or selection 
bias ( 21,22 ), the magnitude of deviations from HWE and its sta-
tistical signifi cance are reported. HWE analysis was performed 
among the healthy controls using the χ 2 test (χ 2 value <3.84 
indicating allele frequency to be in HWE). If a study showed 
a signifi cant deviation of HWE, we planned to perform sensi-
tivity analyses excluding the studies which deviated from HWE 
(if any) as recommended ( 23 ).
 Statistical analysis
 Th e strength of the association between rs738409 and ALD 
prevalence was expressed by OR and their corresponding 95% 
confi dence interval. Random eff ects model was used for ana-
lyzing the pooled data for all the analyses ( 24 ). Heterogene-
ity was measured by the between-study variance using the  I 2 
statistics ( 25 ) with a cutoff  of ≥50% and χ 2 test with  P <0.10 
( 25 ). When there was heterogeneity with only two studies in 
the analysis, we reviewed both the studies for any diff erences 
to explain the heterogeneity. For heterogeneous data on analy-
sis with more than two studies, we took stepwise approach: (i) 
excluding study with diff erent ethnicity on Mestizio subjects, 
(ii) excluding two studies with highest and lowest OR, and 
(iii) meta-regression if needed. To assess the extent of publica-
tion bias, both Egger’s test and the Begg and Mazumdar’s test 
were used on unadjusted analyses ( 26,27 ). Funnel plots were 
assessed by two independent investigators (H.S. and A.K.S.). 
At least two studies in the analyses were needed to examine 
the heterogeneity and three studies for examining any publica-
tion bias.
 To examine independent association of rs738409 and ALD 
spectrum, generalized linear mixed models were built for 
patient demographics using the individual participant data. 
Th is statistical method was chosen to take into account the 
diff erences between the studies and is equivalent to the ran-
dom eff ects model used for our main analysis. Data were not 
controlled for body mass index, given that only two of the fi ve 
studies had information on this variable. First unadjusted odds 
for a particular outcome were assessed comparing the various 
PNPLA3 polymorphisms. Th en, in a stepwise manner age and 
gender were entered into the model to examine independent 
association of PNPLA3 polymorphisms as well as individual 
demographics on the outcome. All statistical analyses were 
performed using the Comprehensive Meta-analysis soft ware 
(Biostat, Englewood, NJ).
 RESULTS
 Baseline study characteristics
 A total of 254 citations were retrieved on initial search. Aft er 
reviewing article titles and abstracts, a total of 14 studies were 
included for full-text review ( Figure 1 ). Of these, four studies 
( 28–31 ) were excluded because of unavailability of data for analy-
sis and/or were not full manuscripts, leaving 10 studies involv-
ing 4,112 patients for this meta-analysis. All 10 studies reported 
PNPLA3 polymorphism data on AC, 4 studies each on ALI and 
HCC, whereas only one study reported data on AFL ( Table 1 ). Of 
the 10 studies, 7 recruited healthy controls ( 18,32–37 ), whereas 
the other 3 had no control group ( 38–40 ). Healthy controls were 
heavy drinkers without liver disease in two studies ( 18,32 ), or 
nondrinkers without liver disease in four studies ( 33,34,36,37 ). 
One study included both drinkers and nondrinkers without liver 
disease ( 35 ). Th e baseline characteristics of the included studies 
are reported in  Table 1 . All studies included subjects with Cau-
casian ethnicity except one study that included Mestizio subjects, 
people from Mexico with mixed European and Native American 
ancestry ( 32 ).
 Assessment of study quality
 Based on the Newcastle–Ottawa Scale, half of the included stud-
ies (fi ve) were considered as high-quality studies ( Supplementary 
Table S1 online). In addition, all seven studies reporting genotype 
frequencies for control population were in HWE ( Supplementary 
Table S2 ).
 PNPLA3 polymorphism (rs738409) in ALD compared with 
healthy controls
 A total of 7 studies involving 2,878 ALD patients and 4,091 con-
trols were analyzed. Compared with healthy controls, prevalence 
of the PNPLA3 polymorphism rs738409 was assessed in patients 
254 Citations identified on initial search and reviewed for study inclusion
- 21 Non-human studies
- 3 Studies were published as abstracts
  (full article missing)
10 Studies included in the
analysis
- 1 Study included HCV patients without
   separate data on ALD population
14 Studies on PNPLA3 polymorphism association with ALD
- 180 Not related to ALD
- 39 Reviews and meta-analysis
240 Citations excluded
4 Studies excluded
 Figure 1 .  Attrition diagram for study inclusion. ALD, alcoholic liver 
disease; HCV, hepatitis C virus; PNPLA3, patatin-like phospholipase 
domain protein 3.
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were homogeneous ( I 2 =0%,  P =0.524) without publication bias as 
assessed by Egger’s test ( P =0.182) or Begg and Mazumdar’s test 
( P =0.120).
 Alcoholic cirrhosis .  Th e OR of rs738409 CG genotype compared 
with CC genotype was 2.09 (1.79–2.44) on comparing patients 
with AC with healthy controls ( Figure 2c ). Data were homogene-
ous ( I 2 =0%,  P =0.989) without publication bias as assessed by Egg-
er’s test ( P =0.17) or Begg and Mazumdar’s test ( P =1.0). Similar 
OR for the rs738409 GG genotype was 3.37 (2.49–4.575;  Figure 
3c ). Data were homogeneous ( I 2 =0%,  P =0.42) without publication 
bias as assessed by Egger’s test ( P =0.46) or Begg and Mazumdar’s 
test ( P =0.31).
 Hepatocellular carcinoma .  Th e OR of rs738409 CG genotype 
compared with CC genotype was 2.87 (1.61–5.10) on comparing 
HCC patients with healthy controls ( Figure 2d ). Data were ho-
mogeneous ( I 2 =35.43%,  P =0.21). Similar OR for the rs738409 GG 
with AFL (1 study), ALI (3 studies), AC (7 studies), and HCC (2 
studies).
 Alcoholic fatty liver .  Th e OR of the rs738409 CG and GG geno-
types as compared with CC genotype in AFL was similar to 
controls when data were pooled from population-based and 
multicenter samples in one study ( 35 ): 0.74 (0.54–1.03) and 0.62 
(0.13–2.93), respectively ( Figures 2a and 3a ). Th e data were ho-
mogeneous for both analyses with respective values of  I 2 =0%, 
 P =0.69 and  I 2 =45.98%,  P =0.17.
 Alcoholic liver injury .  Th e OR of rs738409 CG genotype com-
pared with CC genotype was 1.45 (1.24–1.69) on comparing 
patients with ALI with healthy controls ( Figure 2b ). Data were 
homogeneous ( I 2 =0%,  P =0.995) without any publication bias as 
assessed by Egger’s test ( P =0.569) or Begg and Mazumdar’s test 
( P =0.5). Similar OR for the rs738409 GG genotype was 2.22 
(1.50–3.28) as compared with healthy controls ( Figure 3b ). Data 
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genotype was 12.41 (6.99–22.03) as compared with controls with 
homogeneous data ( I 2 =0%,  P =0.41;  Figure 3d ).
 PNPLA3 polymorphism (rs738409) and severity of alcoholic 
liver disease
 A total of 8 studies involving 3,711 ALD patients were pooled for 
these analyses ( Figure 4a–e ).
 AC vs. AFL .  Th e OR of CG and GG genotypes among AC patients 
compared with AFL was 2.62 (1.73–3.97) and 8.45 (2.52–28.37), 
respectively, in one study ( 35 ) (data not shown in the forest plots).
 AC vs. ALI .  Th e OR of rs738409 CG genotype compared with 
CC genotype was 1.98 (1.24–3.17;  Figure 4a ). Th ere was signifi -
cant heterogeneity among the studies ( I 2 =67.04,  P =0.048). No 
publication bias was detected by Egger’s test ( P =0.11) or Begg 
and Mazumdar’s test ( P =0.12). Sensitivity analysis aft er exclud-
ing the study with the Mestizio subjects ( 32 ) showed similar ef-
fect 2.59 (1.69–3.98) without any heterogeneity ( I 2 =0,  P =0.66). 
Th e OR (95% CI) of developing AC compared with ALI was 3.86 
(1.18–12.60) in the presence of rs738409 GG compared with CC 
genotype ( Figure 4b ). Th e data were heterogeneous ( I 2 =76%, 
 P =0.039). Diff erences on proportion of patients with AC in the 
two studies included in this analysis, ∼ 80% in one study ( 33 ) and 
only 22% in the other study ( 40 ), probably explains this hetero-
geneity. Publication bias could not be done with only two studies 
in this analysis. In addition, OR of rs738409 GG genotype com-
pared with CG genotype was 2.90 (1.53–5.49) in one study ( 40 ).
 HCC vs. AC .  Th e OR of rs738409 CG compared with CC geno-
type was 1.43 (0.76–2.72) ( Figure 4c ). Th e data were homogene-
ous ( I 2 =33,  P =0.22). Similarly, OR of rs738409 GG genotype vs. 
CC genotype was 2.81 (1.57–5.01;  Figure 4d ). However, there was 
signifi cant heterogeneity for this analysis ( I 2 =70.38%,  P =0.018). 
No publication bias was detected by Egger’s test ( P =0.36) or 
Begg and Mazumdar’s test ( P =0.0.490). Sensitivity analysis 
performed aft er excluding the study with the lowest ( 39 ) and 
highest OR showed similar eff ect: 2.91 (1.44–5.86) with no 
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for AC vs. healthy controls: 1.99 (1.61–2.46); and CG genotype 
compared with CC genotype for AC vs. ALI: 2.59 (1.69–3.98).
 Analysis of good-quality studies: on analyzing fi ve good-quality 
studies, data remain unchanged as reported in  Supplementary 
Table S2 .
 Individual participant data analyses .  Individual participant 
data were obtained on 2,033 ALD patients (734 ALI; 1,153 AC 
without HCC; and 146 AC with HCC) from 5 studies ( Table 2 ). 
Data on 487 healthy controls (drinkers with normal blood tests) 
heterogeneity ( I 2 =20.37%,  P =0.26). OR of rs738409 GG vs. CG 
genotype was 2.10 (1.22–3.63) with homogeneous data ( I 2 =0%, 
 P =0.912;  Figure 4e ).
 Subgroup analyses
 Ethnicity analysis .  Aft er excluding the study recruiting Mestizo 
population ( 32 ), pooled eff ect size remained in the same direction 
on the outcomes including this study ( Figures 2b,c and 4a )—CG 
genotype compared with CC genotype for ALI vs. healthy con-
trols: 1.45 (1.17–1.78); CG genotype compared with CC genotype 
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were obtained from two studies ( Table 2 ). Pooled data comparing 
the OR (for AC vs. healthy controls) of CG vs. CC, GG vs. CC, 
and GG vs. CG were 1.84 (1.47–2.31), 4.40 (2.98–6.50), and 2.40 
(1.62–3.55), respectively. Similar OR for HCC vs. healthy controls 
was 2.96 (1.88–4.66), 13.30 (7.61–23.27), and 4.50 (2.71–7.46), 
respectively.
 Generalized linear mixed model analysis on the individual par-
ticipant data showed unadjusted OR for AC vs. ALI comparing CG 
with CC, GG with CC, and GG with CG to be 1.9 (1.3–2.9), 3.0 
(2.0–4.6), and 1.6 (1.1–2.3), respectively. Aft er adding age and gen-
der into the model in a stepwise manner, the signifi cance of the OR 
remained unchanged and in the same direction ( Table 3 ). Partici-
pant age but not the gender independently predicted development 
of cirrhosis ( Table 3 ). Similar unadjusted OR on the development 
of HCC among AC patients was 1.5 (0.5–2.6), 2.9 (0.8–11.1), and 
2.1 (0.1–68.1), respectively. Th e data for HCC remained signifi cant 
with wide confi dence interval probably because of small sample 
size, with data on HCC available on only 358 patients from two 
studies.
 DISCUSSION
 Th e current meta-analysis demonstrates several important fi nd-
ings on the association of the PNPLA3 gene polymorphisms with 
ALD. Compared with controls, prevalence of PNPLA3 polymor-
phisms was higher among patients with ALI, AC, and HCC in AC. 
Furthermore, the prevalence of these polymorphisms was higher 
among patients with AC compared with those with ALI or AFL 
and among AC patients with HCC compared with those without 
HCC. Data on prevalence of PNPLA3 polymorphisms were simi-
lar when drinkers with FL were compared with controls. Individ-
ual participant data also confi rmed these observations.
 Th e disease spectrum in both alcoholic and nonalcoholic fatty 
liver disease is similar and starts with fatty liver change followed 
by infl ammation, fi brosis, and fi nally cirrhosis. Hepatic steatosis 
is seen in 90% of heavy alcohol drinkers and is usually macrove-
sicular ( 41–43 ). Fatty infi ltration develops rapidly within 2 weeks 
and resolves with abstinence ( 44,45 ). Th e similar polymorphism 
prevalence in drinkers with AFL and controls, as found in the cur-
rent meta-analysis, blends well with the fact that AFL is a universal 
phenomenon in alcoholics and is reversible on abstinence. How-
ever, this is not true for ALI, AC, and HCC.
 Stickel  et al. ( 7 ) have reviewed previous studies on alcoholic 
dehydrogenase gene polymorphism in alcoholic patients and 
showed that results were inconsistent. Th e available data do not 
provide clear evidence that demonstrates a contribution of alco-
hol metabolism (alcohol dehydrogenase), antioxidant enzymes 
(CYP2E1, GSTM1, MnSOD), or cytokines (interleukin and tumor 
necrosis factors) genotype polymorphisms to the development of 
ALD ( 7 ). PNPLA3 is the fi rst genetic marker that was confi rmed 
by repeated studies to predispose to ALD and is associated with 
worse severity as we showed in the current meta-analysis.
 Two recent meta-analyses have shown association of PNPLA3 
with advanced fi brosis ( 46,47 ). Heterogeneous data due to inclu-
sion of patients with various liver disease etiologies was a limita-
tion in one study ( 46 ). Furthermore, this study included only three 
studies on alcoholic liver disease ( 29,33,35 ) in comparison with 
fi ve studies in our current analysis ( 18,32–35 ). Our meta-analysis 
provides pooled data comparing ALD patients with healthy con-
trols on the association of PNPLA3 polymorphisms with HCC in 
two studies ( 34,36 ) and AC in four studies ( 34,36,38,39 ). Further-
more, we also examine the association of the remaining spectrum 
of ALD and PNPLA3 polymorphisms including FL and ALI. Our 
study fi ndings on the risk of fi brosis and AC are similar to the 
 Table 2 .  Baseline characteristics and genotype frequencies on individual participant data from 5 studies involving 2,520 patients and 487 
healthy controls 
 Study  N  Age  N  (%) M  BMI  CC:CG:GG 
 Burza  et al. ( 40 )  300 ALD without AC  44.6±11  230 (77)  25.5±4.4  145:126:29 
  84 ALD with AC  54.2±11*  63 (75)  26.7±4.7  19:39:26 
 Nischalke  et al. ( 34 )  80 AC without HCC  57±10.2  69 (86)  26.7±6.8*  32:38:10 
  80 AC with HCC  56.7±10.1  69 (86)  24.9±3.9  17:40:23 
 Falleti  et al. ( 36 )  132 AC without HCC  54±9.4  82 (62)  24.4±4.1  38:64:30 
  66 AC with HCC  60.6±8.4*  62 (94)*  27.3±3.9*  15:26:25 
 Seth  et al. (cases) ( 18 )  375 ALD with AC  49±9.7*  271 (72)  NA  173:170:32 
 Seth  et al. (controls a ) ( 18 )  182  43.4±9.8  133 (73)  NA  119:60:3 
 Tian  et al. (cases) ( 32 )  434 ALD without AC  41±12.4  367 (85)  NA  63:185:186 
  482 ALD with AC  52±11.6  411 (85)  NA  39:179:261 
 Tian  et al. (controls a ) ( 32 )  305  39±12.7  257 (84)  NA  59:155:89 
 AC, alcoholic cirrhosis; ALD, alcoholic liver disease; BMI, body mass index; HCC, hepatocellular carcinoma; NA, not available. 
 * P <0.05. 
 a Drinkers with normal blood tests. 
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second meta-analysis except for lower OR for the GG genotype. 
Th is may be as this analysis included three citations published as 
abstracts ( 29–31 ) that were not included in our current analysis. 
In another meta-analysis, PNPLA3 polymorphisms among cir-
rhotics have been associated with HCC ( 48 ). Our meta-analysis in 
addition to confi rming the fi ndings from this study also examines 
the HCC risk in alcoholics compared with healthy controls. Fur-
thermore, we also examined the association of PNPLA3 polymor-
phisms with the other spectrum of ALD.
 Our analysis may be limited by the possibility of publication 
bias. In order to minimize this possibility and subsequently over-
estimation of the true eff ect size because of negative study identifi -
cation failure ( 49 ), we combined searches from PubMed/Medline, 
Embase, and Cochrane with manual searches. Although we used 
procedures in agreement with current guidelines, we cannot for-
mally rule out the possibility that we missed studies that were not 
accessible ( 49 ). Another limitation of this meta-analysis is the inclu-
sion of case–control studies in which the potential for biases (e.g., 
selection and reporting) is higher when compared with randomized 
trials and they are more inherent to confounding factors. In the 
current analysis, the rs738409 genotype frequencies in the control 
group that followed the HWE is a strength of this study as sampling 
bias or coincidental gene association because of population strati-
fi cation could be excluded ( 39 ), but some authors have shown that 
HWE testing is not a reliable way of detecting genotyping error and 
can certainly not exclude population stratifi cation ( 21,50 ). Finally, 
we were not able to retrieve all the individual participant data 
(only 46% of all individual participant data were obtained) from 
the included studies, especially the largest one by Stickel  et al. ( 35 ) 
(1,419 patients). Th erefore, we used the individual participant data 
for only the subgroup analyses and not our main outcome analyses.
 In conclusion, the PNPLA3 rs738409 polymorphism is associ-
ated with increased risk for the entire spectrum of ALD among 
drinkers, and increased propensity for AC and HCC in ALI 
patients. Studies are needed to clarify the association of PNPLA3 
and steatosis in alcohol drinkers. Th e  PNPLA3 gene may poten-
tially be a therapeutic target in ALD and in the selection of donor 
organs for transplantation of patients with ALD.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  The  patatin-like phospholipase domain protein 3 ( PNPLA3 ) 
gene polymorphism confers risk of steatosis. 
 ✓  This is also associated with cirrhosis and hepatocellular 
carcinoma (HCC) in alcoholic liver disease (ALD). 
 WHAT IS NEW HERE 
 ✓  PNPLA3 polymorphism increases risk for entire spectrum 
of ALD. 
 ✓  The magnitude of this association increases in parallel 
to increasing severity of liver disease from alcoholic liver 
injury to alcoholic cirrhosis to hepatocellular carcinoma. 
 ✓  Data on association of PNPLA3 polymorphisms with 
alcoholic fatty liver are inconsistent. 
 ✓  Data remained unchanged for separate analyses (i) on 
individual patient data from fi ve studies and (ii) on fi ve 
good-quality studies. 
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